Evidence map›Paper›PMID 42038730›Full record

ArticleCureus2026

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis.

Homa Timlin, Abbal Koirala, Duruvu Geetha, Antoine Azar, Andrew Mener

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Homa TimlinRheumatology, Johns Hopkins University School of Medicine, Baltimore, USA.
Abbal KoiralaNephrology, Johns Hopkins Bayview Medical Center, Baltimore, USA.
Duruvu GeethaNephrology, Johns Hopkins University School of Medicine, Baltimore, USA.
Antoine AzarAllergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, USA.
Andrew MenerOncology, Maryland Oncology Hematology, Columbia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Achieving remission or low disease activity in systemic lupus erythematosus reduces long-term organ damage, disease flares, and corticosteroid exposure. Kidney involvement from lupus nephritis is often progressive and associated with adverse long-term outcomes. Early, effective immunosuppression during the active inflammatory phase of lupus nephritis is linked to improved renal outcomes. Although voclosporin and obinutuzumab have each demonstrated efficacy in lupus nephritis, real-world data on their combined use remain limited. Here, we report outcomes in three patients with active lupus nephritis who were treated with both Food and Drug Administration (FDA)-approved agents.

Indexed as

lupus nephritisobinutuzumabproteinuriasystemic lupus erythematosusvoclosporin

Identifiers

PMID42038730
PMCPMC13107494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.